Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Mycophyto is a French company founded in 2016, co-created by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise. Based in Mougins, the company focuses on developing biological solutions aimed at revitalizing soil and enhancing plant growth. Mycophyto specializes in analyzing soil to identify indigenous fungi and pathogens beneficial for plant development. By isolating, multiplying, and inoculating mycorrhizae, the company provides customized products and support services for new agricultural systems. This innovative approach allows plant researchers to cultivate crops and herbs using natural soil microorganisms, minimizing reliance on chemical fertilizers and promoting sustainable agricultural practices.
Guerbet is a healthcare company specializing in medical imaging, with a focus on manufacturing and marketing contrast agents for diagnostic purposes. With nearly 90 years of experience, it is the only pharmaceutical group dedicated solely to medical imaging globally, operating in almost 80 countries through subsidiaries and distributors. Guerbet's product portfolio includes a comprehensive range of contrast agents for various imaging modalities, such as X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company also offers injectors and related medical devices designed to enhance patient diagnosis and prognosis. Its well-known brands include Xenetix, Optiray, Dotarem, and others, all aimed at improving the quality of life for patients.
Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.
Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.
Phagos Biotech is a biotechnology company focused on combating antibiotic resistance through innovative bacteriophage solutions. The company develops customizable treatments designed to replace traditional antibiotics in animal farming, specifically targeting bacterial infections in seafood and livestock. By utilizing bacteriophages, which are natural predators of bacteria, Phagos aims to provide an efficient and sustainable alternative for health professionals dealing with incurable and life-threatening infections. This approach addresses the urgent need for effective treatments in the face of rising antibiotic resistance, contributing to safer agricultural practices and improved animal health.
Priothera Ltd is a clinical-stage company focused on developing orally administered sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. Founded in 2020 and based in Dublin, Ireland, with an additional location in Saint Louis, France, the company seeks to improve patient outcomes by enhancing the curative potential of allogeneic hematopoietic stem cell transplantation. Its lead product, mocravimod, is designed to reduce the egress of specific T cell subsets from lymphatic tissues, thereby providing dual inhibition of graft versus host disease while promoting graft versus leukemia effects. Through this innovative approach, Priothera aims to deliver significant advancements in the treatment of patients with blood cancers.
Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.
Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.
Spartha Medical is a medical technology company focused on developing eco-friendly, invisible coatings designed for medical devices and consumer products to mitigate microbial and inflammatory risks. Utilizing natural biopolymers, the company’s innovative coatings possess antibacterial, antiviral, and anti-inflammatory properties, providing an effective solution for infection control. The technology relies on a patented method of supramolecular assembly, enabling precise control over the properties of the coatings based on specific applications. This approach allows for the creation of multifunctional and easy-to-apply surface treatments that help healthcare institutions maintain disease-free environments on medical devices.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Perha Pharmaceuticals is a biotechnology company dedicated to the research and development of innovative therapies aimed at addressing hearing loss and cognitive disorders. The company focuses on preventing cisplatin-induced hearing loss and developing treatments for cognitive conditions related to Down syndrome and Alzheimer's disease. Perha Pharmaceuticals leverages natural marine substances in its research, with chemists and biologists optimizing molecules derived from marine organisms to create effective kinase inhibitors. This approach underscores the company's commitment to advancing medical treatments and improving patient care in areas of significant unmet need.
NATUROPERA's vision is therefore to help change consumption to restore the balance of life. compositions and formulations respectful of the environment.
Private Equity Round in 2021
Provepharm life Solutions is a truly unique life sciences research and pharma company, dedicated to a new era of discovery. We are a new global leader in human health with new Life Solutions, manufactured and developed from our core technology: Molecule Vitalization. As PROVEPHARM LIFE SOLUTIONS, we are building a new powerhouse for Research Services, Manufacturing Services and Speciality Care.
PEP-Therapy SAS is a biotechnology company based in Evry, France, founded in 2014. The company specializes in the development of cell penetrating and interfering peptides (CP and IP) aimed at delivering targeted therapies for severe diseases, particularly cancer. One of its key products is DPT-PEP1, a peptide designed to inhibit Caspase-9/PP2A protein interactions, effectively triggering apoptosis in cancer cells while preserving the functionality of healthy cells and other signaling pathways. By focusing on the intracellular delivery of these peptides, PEP-Therapy aims to address critical pathological mechanisms, offering a promising approach to cancer treatment.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Manufacturer of nitrogen products and fertilizers intended to restore fertility and natural health of all soils. The company engages in the production of a range of crop protection products including soil conditioners, microbial concentrates, natural seed protection products, and more, enabling farmers to improve seed and seedling resistance to seedling diseases and pest attacks.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
Aqemia is a Paris-based start-up founded in 2019 that specializes in in silico drug discovery. The company aims to accelerate the development of innovative therapeutic molecules by utilizing advanced generative AI and unique Statistical Mechanics algorithms. Aqemia's platform is designed to predict the affinity between drug candidates and their therapeutic targets with a speed and accuracy that is significantly superior to traditional methods. This capability allows researchers to efficiently guide the generation of compounds that have a higher likelihood of success in drug development. As a spin-off from École Normale Supérieure, Aqemia leverages eight years of research, drawing on expertise from fields such as Medicinal Chemistry, Statistical Mechanics, and Artificial Intelligence. The company's mission is to enhance the drug discovery process and improve the chances of finding effective treatments for various diseases.
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options.
To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases.
Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options.
To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
Olgram is a biotechnology company focused on developing innovative solutions to combat chronic bacterial infections and address immune deficiencies resulting from conditions like traumatic brain injury and concussions. The company specializes in marine molecules, particularly those derived from algae, to create new products that target dormant bacteria responsible for infectious relapses. Through its research, Olgram is pioneering a new class of anti-infectives aimed at effectively eliminating persistent bacterial strains. Its dual approach not only seeks to treat stubborn bacterial infections but also aims to enhance immune responses, thereby contributing to more effective treatments for patients suffering from various infectious diseases.
PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Seekyo SAS is a biotechnology company based in Poitiers, France, established in 2018. The company specializes in developing innovative treatment options for cancer patients, focusing on the creation of smart molecular systems. These systems are designed to transport potent anticancer agents selectively, targeting the microenvironment of solid tumors while minimizing harm to healthy tissues. Seekyo's approach utilizes advanced technologies such as antibody drug conjugates and small molecule drug conjugates, which specifically recognize cancer cell surface markers and tumor microenvironment characteristics. This allows for the controlled release of therapeutic agents directly at the tumor site, enhancing treatment efficacy and reducing adverse effects. By prioritizing the safety and effectiveness of chemotherapy, Seekyo aims to improve the overall treatment experience for cancer patients.
Operator of a biotechnological therapeutic platform intended to provide financial assistance and operational excellence to early-stage projects. The company's platform identifies, selects, and incubates early-stage biotechnology projects that focus on selected therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology, enabling startups to further develop their medicinal and drug research process.
Activ'Inside manufactures botanical ingredients and formulations to commercialize the products for well-being markets.
Based in the Bordeaux area (France), Activ’Inside is an independent health food-tech company specialized in the development, production, and marketing of natural active ingredients, mainly from grape and saffron, for the health nutrition industry.
NovAliX is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry's outsourcing needs from discovery to manufacturing. With proprietary SPR technology, X-ray protein crystallography, supramolecular mass spectrometry and chemistry, NovAliX offers comprehensive integrated services for small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
Kayentis SAS specializes in electronic clinical outcome assessment (eCOA) and electronic data capture solutions, primarily serving pharmaceutical companies and clinical trial organizations. Founded in 2003 and headquartered in Meylan, France, with additional offices in Boston and Tokyo, the company provides a range of tools designed to streamline clinical trials. Their offerings include Clin'form, a web portal for data management; ePEN, a data capture solution that reduces study duration and costs; and Kayentis Tablet for site-based eClinRO and ePRO data collection. Kayentis also offers project management, design and validation services, training, and comprehensive data management, enhancing the efficiency of clinical trial data collection for sponsors and operators.
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.
SideROS, a biotechnology company, engages in research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells. It develops ironomycin, a chemical molecule, which disturbs iron homeostatis, involved in the maintenance of persister cancer cell, and provokes cell death by ferroptosis. The company was incorporated in 2019 and is based in Paris, France.
Synapse Medicine is a company based in Bordeaux, France, founded in 2017, that develops an online platform aimed at assisting healthcare professionals, including doctors and pharmacists. The platform provides reliable and up-to-date information about medications, allowing users to analyze prescriptions in real-time and enhance the safety of drug therapies. By offering access to critical medical intelligence, Synapse Medicine enables healthcare providers to make informed decisions and ensure better outcomes for patients through virtual medical assistance.
Xenothera SAS is a biotechnology company based in Nantes, France, focused on advancing immunological treatments through its innovative platform. Established in 2014, the company specializes in developing therapeutic solutions targeting various medical areas, including immunomodulation and infectious diseases. Its approach leverages proprietary Glyco-Humanized Antibodies and integrates expertise in animal genetics and immunology to create a new generation of hyperimmune polyclonal sera. By renovating passive immunotherapy, Xenothera aims to address unmet medical needs and facilitate the rapid development of new immunological therapies. The company's comprehensive platform allows for streamlined processes, from selecting immunogens to purifying immunoglobulins, ultimately aiming for expedited market authorization.
ABC Transfer is a biopharmaceutical company that specializes in the development of Rapid Transfer Systems (RTS) for the pharmaceutical industry. The company manufactures secure transfer systems designed specifically for sterile drug manufacturing and bioprocessing. Its innovative solutions include alpha doors, beta containers, and single-use bags, all built on patented designs. These systems enhance sterility assurance, improve operator safety, and increase overall efficiency in drug manufacturing processes. Through its focus on secure and efficient transfer methods, ABC Transfer aims to support the biopharmaceutical industry's critical need for reliable and safe drug production.
Syndivia SAS develops antibody-drug conjugates (ADC) for cancer treatment. The company provides therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks. It offers lead programs such as SDV1001 for pancreatic cancer and colorectal cancer and SDV1101 for breast cancer and liposarcoma. Syndivia SAS was incorporated in 2014 and is based in Illkirch-Graffenstaden, France.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Founded in 2009 and based in Lyon, France, Fab’entech is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] aimed at treating emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech provides healthcare institutions with effective therapeutic options for emergency situations. As a member of the LyonBiopôle cluster, the company contributes to advancements in medical technology and immunotherapy.
Urania Therapeutics is a biopharmaceutical company focused on developing innovative therapies for genetic diseases and cancers caused by mutations. The company specializes in the identification and creation of readthrough compounds that address premature stop codons during protein synthesis. By facilitating the production of full-length proteins, these compounds aim to treat a variety of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its unique structure-based drug design platform, Urania Therapeutics seeks to restore the production of functional proteins, thereby offering new therapeutic options for patients with these challenging conditions.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Aelis Farma S.A.S. is a biotechnology company based in Bordeaux, France, established in 2013. The company specializes in the research and development of pregnenolone derivatives aimed at treating cannabis addiction. Aelis Farma is recognized for its innovative approach in developing signaling-specific therapeutics that target G protein-coupled receptors (GPCRs), particularly the CB1 receptor, which is widely expressed in the brain. By focusing on these receptors, Aelis Farma aims to create treatments that can selectively modulate signaling pathways, minimizing unwanted side effects commonly associated with conventional GPCR-targeting drugs. The company's work addresses critical needs in the treatment of brain diseases and addiction.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
AlgoTherapeutix SAS is a biotechnology company founded in 2018 and located in Suresnes, France, focused on developing innovative topical treatments for complex pain conditions. The company's primary product, ATX01, is designed to alleviate peripheral neuropathic pain caused by chemotherapy. By targeting the damaged nerve fibers in the skin, AlgoTherapeutix aims to provide effective pain relief while minimizing the systemic side effects associated with oral medications. The company's approach also addresses other pain syndromes, such as erythromelalgia, thereby offering medical practitioners new options to enhance patient care for those suffering from chemotherapy-induced peripheral neuropathy.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Microphyt, founded in 2007 and headquartered in Baillargues, France, specializes in the research, development, production, and marketing of natural algae-based products. The company focuses on microalgae and other photosynthetic microorganisms, targeting sectors such as beauty care, food, health, and energy. Its offerings include dietary supplements and products aimed at promoting weight loss and enhancing brain health. Utilizing industrial-scale cultivation techniques, Microphyt preserves the integrity of microalgae cells to produce biomass and extracts in commercial quantities. This approach enables the healthcare industry to meet the growing demand for innovative personal care and food products.
PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.
Feroscan was set up in 2014 at the initiative of its four founders bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian, triple negative breast and NSCL cancers. Feroscan’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and relies on a strong academic and industrial network worldwide to develop clinical applications of its research programs.
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.
NH TherAguix SAS, a clinical stage pharmaceutical company, develops nanomedicines for cancer, combining imaging, and radiotherapy. It offers AGuIX, a nanoparticle that is designed to improve the localization of solid tumors and the outcomes of radiation therapy by intravenous injection; allows the radiation therapy treatment for patient to determine the optimal moment to perform the irradiation; and allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues. The company was founded in 2015 and is based in Villeurbanne, France.
Igyxos S.A., founded in 2017 and based in Nouzilly, France, focuses on developing innovative pharmaceuticals and medical technologies aimed at improving human fertility. The company engages in all stages of drug development, from discovering promising targets to identifying lead compounds, including small molecules and antibodies. Igyxos specializes in monoclonal antibodies that enhance the activity of gonadotropins and hormones critical for reproduction. Additionally, the company supports the transition of potential drug candidates through the pre-clinical and clinical phases of development, aiming to address the increasing global demand for effective infertility solutions for both men and women.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
PHENIX SAS is a social enterprise based in Paris, France, established in 2014. The company focuses on reducing waste and promoting a circular economy by enabling the second life of products, including food and non-food items. With a team of around 100 dedicated employees, PHENIX provides a range of services to over 1,000 professional clients across various sectors, including retail, industrial, and events. Its offerings include the valuation of unsold products and waste, access to a digital platform, and comprehensive studies and advisory services. PHENIX's clients encompass industries, wholesalers, shopping centers, caterers, and event agencies, all of which benefit from its collaborative and logistical solutions aimed at effective waste management.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.
Discngine provides scientific computing consulting services & solutions for Life Sciences Research. They are specialized in the integration of scientific software like BIOVIA - Accelrys Pipeline Pilot, Chemaxon, CambridgeSoft and industry standards like Oracle database or Tibco Spotfire.
PILI Inc. researches and manufactures bio-fabricated colors by using microorganisms. The company designs enzymes and fermentation biotechnologies to efficiently transform sugar into renewable and long-lasting colors. PILI Inc. produces renewable dyes and pigments. The company was founded in 2012 and is based in Paris, France.
Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections.
Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.
Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.
Private Equity Round in 2017
Belovia has designs, manufactures and markets medical devices and equipment (electronic stocking donners, light solutions for physical mobilization, etc.).
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
OSE Immunotherapeutics is a clinical-stage biotechnology company based in Nantes, France, dedicated to the development of innovative immunotherapies aimed at immune activation and regulation. The company's product portfolio includes Tedopi, an immunotherapy currently in Phase III clinical trials for lung cancer and Phase II trials for pancreatic cancer. OSE-703, a humanized monoclonal antibody, is in preclinical development for various cancers, while BI 765063 is undergoing Phase I trials for solid tumors. Additionally, FR104 is in Phase I trials for rheumatoid arthritis, and OSE-127 is in Phase I for inflammatory autoimmune diseases. OSE Immunotherapeutics has established collaborations with several prestigious organizations, including GERCOR and Memorial Sloan Kettering Cancer Center. The company was previously known as OSE Pharma SA before rebranding in May 2016.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Alkion BioInnovations specializes in the production of natural plant active ingredients for pharmaceutical applications, utilizing proprietary patented semi-industrial technologies. Established in 2017 following the acquisition of Alkion BioPharma by Evonik Industries AG, the company focuses on transforming non-GMO plants into a source of pharmacologically active compounds. Its innovative technology supports the development of disruptive nutrition, non-cosmetic oil, and agrochemical solutions. Alkion BioInnovations holds exclusive rights to these applications, catering to the pharmaceutical and agri-food markets, and has garnered interest from various sectors, including cosmetics, for its potential to revolutionize ingredient production.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.
Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.
Antabio SAS is a biopharmaceutical company based in Labège, France, focused on developing drugs to combat antibiotic-resistant bacterial infections. Established in 2009, the company specializes in creating inhibitors that target bacterial metalloenzymes to restore the efficacy of existing antibiotics against critical pathogens. Among its key developments are a Metallo Beta-Lactamase inhibitor designed to enhance carbapenem treatment, a Serine Beta-Lactamase inhibitor with broad coverage against key enzymes, and Pseudomonas Elastase inhibitors, which aim to reduce the frequency and severity of exacerbations in patients with Pseudomonas infections. Antabio's innovative approach addresses significant unmet medical needs in the fight against nosocomial infections, particularly those caused by drug-resistant bacteria.
Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.
Sigmaphi is a specialized manufacturer of electromagnetic equipment focused on serving the scientific and healthcare sectors. The company designs and produces a range of products including electro-magnets, pulsed injection systems, radiofrequency amplifiers, magnetic systems, power supplies, and particle beam transport lines for particle accelerators. By leveraging advanced technology, Sigmaphi aims to optimize the operations of its clients, facilitating enhanced performance in various applications related to particle acceleration.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.